• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Temozolomide: a novel oral alkylating agent.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Danson, Sarah
    Middleton, Mark R
    Affiliation
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 9BX, UK.
    Issue Date
    2001-06
    
    Metadata
    Show full item record
    Abstract
    Temozolomide is an imidazotetrazine with a mechanism of action and efficacy similar to dacarbazine (DTIC). However, it differs from DTIC in that it can be taken orally, degrades spontaneously to an active metabolite and penetrates the blood-brain barrier. It is well tolerated, making it a suitable candidate for combination chemotherapy. Trials to date have focussed on its activity in advanced metastatic melanoma and high-grade malignant glioma. Investigations into other indications, in particular solid tumors with central nervous system metastases, are ongoing. Studies of new drug schedules and of drugs to ameliorate temozolomide resistance offer the prospect of increased efficacy.
    Citation
    Temozolomide: a novel oral alkylating agent. 2001, 1 (1):13-9 Expert Rev Anticancer Ther
    Journal
    Expert Review of Anticancer Therapy
    URI
    http://hdl.handle.net/10541/82499
    DOI
    10.1586/14737140.1.1.13
    PubMed ID
    12113120
    Type
    Article
    Language
    en
    ISSN
    1473-7140
    ae974a485f413a2113503eed53cd6c53
    10.1586/14737140.1.1.13
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Temozolomide and treatment of malignant glioma.
    • Authors: Friedman HS, Kerby T, Calvert H
    • Issue date: 2000 Jul
    • Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
    • Authors: Agarwala SS, Kirkwood JM
    • Issue date: 2000
    • New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
    • Authors: Spiro T, Liu L, Gerson S
    • Issue date: 2000 Jul-Sep
    • New approaches for temozolomide therapy: use in newly diagnosed glioma.
    • Authors: Stupp R, Newlands E
    • Issue date: 2001 Aug
    • Temozolomide for Treating Malignant Melanoma.
    • Authors: Li RH, Hou XY, Yang CS, Liu WL, Tang JQ, Liu YQ, Jiang G
    • Issue date: 2015 Sep
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.